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Abstract
Background: The incidence of gallbladder carcinoma in cirrhotics is unknown. Known risk factors
are primary sclerosing cholangitis and polypoid masses.
Case presentation: A sixty year old with primary sclerosing cholangitis, cirrhosis, and gallbladder
polyps underwent liver transplantation. A polypoid lesion measuring 1.5 × 0.5 cm was found on the
fundus of the gallbladder. Histological examination revealed moderately differentiated
adenocarcinoma with full thickness penetration of the gallbladder encroaching liver parenchyma.
Angiolymphatic invasion was noted. The lymph nodes, the cystic duct and the common duct were
free of tumor (T3N0M0). Extensive evaluation did not demonstrate metastasis. No chemotherapy
was given. He is currently six years post procedure and free of disease.
Conclusion: "Incidentally" discovered stage IIA gallbladder carcinoma may not negatively affect
long term survival after liver transplantation.
Background
Between 6000 and 7000 cases of gallbladder carcinoma
are diagnosed yearly in the United States. Advanced gall-
bladder carcinoma (GBC) usually portends an extremely
grave prognosis [1]. Recent reports in the literature have
demonstrated improved results after aggressive surgical
resection for stage II–IV lesions [2]. Although there are
sporadic reports of incidental gallbladder carcinoma
found after liver transplantation, no consensus exists on
the proper treatment for those patients found to have gall-
bladder carcinoma with cirrhosis.
Major risk factors for the development of GBC include
polypoid lesions and sclerosing cholangitis (PSC). Larger
polyps, especially in the setting of PSC (with or without
cirrhosis) have a greater than 50% chance of harboring
malignancy [3]. Primary sclerosing cholangitis is a chronic
progressive disorder of unknown etiology that is charac-
terized by inflammation, fibrosis, and stricturing of
medium size and large ducts in the intrahepatic and extra-
heptic biliary tree [4]. The only definitive therapy is liver
transplantation. There are no biochemical or clinical risk
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factors for the development of hepatobiliary cancer in
patients with PSC [5].
Ultrasound and CT scan are usually relied upon to diag-
nose polypoid lesions and other abnormalities of the gall-
bladder. However, due to chronic cholecystitis, wall
thickening and gallstones, the lesions are frequently
missed [6].
We present the case of a gentleman with primary scleros-
ing cholangitis and a polypoid lesion of the gallbladder
who underwent liver transplantation. Pathology revealed
a T3N0M0 (AJCC 2002) gallbladder carcinoma. He is cur-
rently six years post procedure without any signs of recur-
rent disease. Although there are case presentations of
patients with incidental and early (T1 and T2) lesions
demonstrating excellent medium term survival, this is the
first report of a patient with a T3 lesion attaining six year
disease free survival after liver transplantation.
Case presentation
A sixty year old male diagnosed with primary sclerosis
cholangitis and cirrhosis caused by primary sclerosing
cholangitis after an ERCP and liver biopsy in June of 1999.
A computerized tomographic scan (CT) revealed a cir-
rhotic liver, enlarged spleen, coronary vein and gallblad-
der wall varices and a polypoid mass of the gallbladder
confirmed on follow up ultrasonography. Due to the
patient's debilitated state and risk for life threatening
decompensation, the decision was made not to remove
the gallbladder.
He was listed for liver transplantation as status 2A. On
November 16th, 1999 an ABO compatible size matched
organ was allocated to him. The transplant was performed
with the conventional technique with venovenous bypass.
In the explanted liver, a polypoid mass, which measured
1.5 × 0.5 cm, was found on the fundus of the gallbladder.
Histological examination revealed moderately differenti-
ated adenocarcinoma with full thickness penetration of
the gallbladder encroaching (within millimeters) liver
parenchyma. Angiolymphatic invasion was confirmed.
(Figures 1, 2, 3) Examination of the hepatic hilar lymph
nodes, common duct, cystic duct and the remainder of the
liver did not show any metastasis (T3N0M0, Stage IIA;
AJCC 2002).
Extensive metastatic evaluation was also negative. The
patient recovered uneventfully with triple immunosup-
pression (Tacrolimus, mycophenalate, and prednisone)
and received no chemotherapy.
Patient was being followed closely in the liver transplant
clinic and had normal liver function tests until his demise
in June of 2006. A CT scan performed June 2006 was neg-
ative for any signs of gallbladder carcinoma.
Discussion
Primary sclerosing cholangitis (PSC) is a chronic choles-
tatic disease that progresses to end – stage liver disease.
The only definitive form of therapy is liver transplantation
(LT). LT results in patient and graft survivals approaching
that of other indications [7]. Patients with sclerosing
cholangitis are at increased risk for cholangiocarcinoma
(CC)[8]. CC develops in 10–15% of PSC patients fol-
lowed for five years and up to 30% of patients followed
for more than 10 years [9]. Other malignancies associated
with PSC include colon, hepatocellular, fibrolamellar,
and gallbladder carcinoma [10].
The exact risk of gallbladder carcinoma with sclerosing
cholangitis is unknown. In a study of 25 PSC patients with
a biliary malignancy, eight of the tumors were located in
the gallbladder [11]. A recent Canadian report docu-
mented the presence of an occult GBC in one out of 111
patients transplanted for primary sclerosing cholangitis.
The stage of that cancer is unknown [12]. The Johns Hop-
kins group documented one case of GBC out of 146
patients (not all transplant recipients) with primary scle-
rosing cholangitis treated over a 14 year time span [9]. In
127 transplanted patients with PSC at UCLA no gallblad-
der carcinomas were reported [7]. In 51 patients trans-
planted by the Lahey group over a 17.5 year period, one
was found to have an "incidental" carcinoma of the gall-
bladder [13]. The same authors published case presenta-
tions nine years prior of two gallbladder carcinomas
found incidentally after recipient hepatectomy. One
patient with PSC (presumably the same patient as in the
aforementioned report) had a papillary growth with a
T2NoMo gallbladder carcinoma. The other patient was
transplanted for primary biliary cirrhosis and was harbor-
ing a T1NoMo GBC. Both patients survived long term (2.5
years) without any further interventions [14]. In 1998, a
case presentation was published of a woman with PSC
and cirrhosis who underwent a cholecystectomy for a new
11 × 13 mm polyp and was found to have a GBC infiltrat-
ing all layers (a T2 lesion) and invading local lymphatic
vessels. One month later an orthotopic liver transplant
was performed and she was free of disease at 24 months
[15].
Our patient's GBC was also discovered incidentally. How-
ever, he appears to have more extensive spread than previ-
ously documented in the literature.
GBC is the most common malignant tumor of the biliary
tract [16]. The incidence in the United States is about 2.5
per 100,000 and is associated with approximately 2500
deaths per year in the U.S. [17]. In most series the five yearWorld Journal of Surgical Oncology 2006, 4:45 http://www.wjso.com/content/4/1/45
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survival is less than 10%. In 15–20% of patients it is dis-
covered incidentally after routine cholecystectomy. Gall-
bladder carcinoma is found pathologically after 1–2% of
all cholecystectomies. Gallstones, choledochal cysts, calci-
fied gallbladders, anomolous pancreaticobiliary duct
junctions, obesity, estrogens, and smoking [18] have been
linked with the development of this disease.
The presence of polyps is also a predisposing factor for
GBC [19]. The prevalence of polypoid lesions of the gall-
bladder is up to14% [5]. Most are benign, however those
which are greater than 10 mm in diameter have the great-
est malignant potential [12]. Endoscopic ultrasound may
be superior to standard ultrasound and CT scan for diag-
nosis [6]. According to one report, gallbladder polyps in
patients with primary sclerosing cholangitis are frequently
(57% of polyps) malignant [3]. The mean size of the
lesions in this study was 21 mm. In our patient, the polyp
was appreciated on both ultrasound and CAT scan and
was greater than 10 mm in its greatest dimension. How-
ever, since the risk of decompensation after cholecystec-
tomy was significant, the decision was made not to
remove the lesion prior to transplantation.
Most carcinomas of the gallbladder are adenocarcinomas.
The most common mode of spread is direct invasion into
liver segments IV and V and into the duodenum, colon,
anterior abdominal wall and common hepatic ducts.
Metastasis may involve the lymph nodes posterior to the
pancreas and the portal vein. Fortunately, our patient did
not demonstrate such spread.
Gallbladder carcinoma is usually diagnosed on ultra-
sound [6]. This modality however is notoriously inaccu-
rate [20]. Patients with PSC are reported to have large,
thickened and chronically inflamed gallbladders [21],
perhaps exacerbating the inability to preoperatively diag-
Infitrating gallbladder carcinomia (H & E 40 ×) Figure 1
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nose these lesions. The extent of carcinoma spread is eval-
uated with CT scan.
In our case, the lesion was suspected but obfuscated by the
gallbladder varices and chronic cholecystitis frequently
seen in this scenario. The AJCC 2002 TNM classification is
used in order to stage gallbladder carcinoma.
T1 lesions are best treated with simple cholecystectomy.
Five-year survival approaches 100%.
Patients with T2 lesions should have a radical cholecystec-
tomy. This will increase five year survival from 10–40%
(seen with simple cholecystectomy) to 80–90% [2]. T3 or
T4 lesions may require a formal segmentectomy for cure.
Common duct excision and hepaticojejunostomy may be
necessary for lesions involving the cytic duct common
duct confluence. Five-year survivals ranging as high as
60% for T3 lesions and 25% for T4 lesions have been doc-
umented after radical resection. Some researchers believe
that radical surgery should only be attempted if there is no
lymph node involvement and if complete extirpation of
the lesion is possible [2]. Others believe that excellent
results (80% five year survival) can be obtained despite
positive lymph nodes [22]. Patients at the Mayo clinic
who underwent a radical cholecystectomy had a signifi-
cantly longer median survival (24 months) than patients
who had a simple cholecystectomy (6 months) or noncur-
ative treatment (4 months). This was true for all stages
except stage 1[22]. Survival rates without surgery are dis-
mal [20,24].
In our case of T3 gallbladder carcinoma with PSC cirrho-
sis, liver transplantation may have cured the patient.
Chemotherapy has not been widely studied for the treat-
ment of gallbladder carcinoma. Gemcitabine has shown
promise in the treatment of biliary tract cancers and may
have a role in treating GBC. 5-FU and cisplatin are the
standard chemotherapeutic agents used [25]. At this
Angiolymphatic Invasion (H & E 400 ×) Figure 2
Angiolymphatic Invasion (H & E 400 ×).World Journal of Surgical Oncology 2006, 4:45 http://www.wjso.com/content/4/1/45
Page 5 of 6
(page number not for citation purposes)
point, absent the demonstration of therapeutic efficacy,
no specific chemotherapeutic regimen can be recom-
mended. In the setting of liver transplantation, chemo-
therapy is problematic because of toxicity and lack of
proven efficacy. For this reason, no chemotherapy was
administered to our patient.
Given the dismal results for known cholangiocarcinoma
with liver transplantation [7] and the overall poor survival
for extensive gallbladder carcinoma in the general popu-
lation [16], liver transplantation is not recommended for
known GBC.
Conclusion
We present the case of a sixty year old gentleman with pri-
mary sclerosing cholangitis and a polypoid lesion of the
gallbladder. He successfully underwent liver transplanta-
tion and was found to be harboring a T3N0M0 gallblad-
der carcinoma. He is currently six years post procedure
and has no evidence of disease. Others have reported
excellent medium term survival for incidental (T1 and T2)
lesions discovered on explant. This case demonstrates that
incidental gallbladder carcinoma (like incidental cholan-
giocarcinoma) may not negatively affect long term sur-
vival after liver transplantation. However, further studies
are needed in order to evaluate the usefulness of liver
transplantation in the setting of advanced gallbladder car-
cinoma discovered before transplantation.
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